EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
-1.38%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$843M
AUM Growth
+$843M
(-18%)
Cap. Flow
-$112M
Cap. Flow
% of AUM
-13.23%
Top 10 Holdings %
Top 10 Hldgs %
64.12%
Holding
79
New
8
Increased
25
Reduced
24
Closed
13
Top Buys
| 1 |
Natera
NTRA
|
$41.6M |
| 2 |
GSK
GSK
|
$39.9M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$23.5M |
| 4 |
Illumina
ILMN
|
$13.7M |
| 5 |
Seres Therapeutics
MCRB
|
$12.4M |
Top Sells
| 1 |
AstraZeneca
AZN
|
$67.4M |
| 2 |
Avantor
AVTR
|
$20.5M |
| 3 |
SPDR S&P Biotech ETF
XBI
|
$20.3M |
| 4 |
argenx
ARGX
|
$16.1M |
| 5 |
Tandem Diabetes Care
TNDM
|
$15.2M |
Sector Composition
| 1 | Healthcare | 98.6% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BHVN
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $96.3M | 8.35% | 637,139 +4,345 | +0.7% | +$657K |
|
|
2
GSK
GSK
$79.9B
| $87.3M | 7.56% | 2,939,070 +1,344,949 | +84% | +$39.9M |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $78.6M | 6.81% | 1,269,591 +380,008 | +43% | +$23.5M |
|
|
4
Natera
NTRA
$23.1B
| $62.5M | 5.41% | 1,425,602 +949,947 | +200% | +$41.6M |
|
5
United Therapeutics
UTHR
$13.8B
| $53.4M | 4.63% | 255,226 -55,608 | -18% | -$11.6M |
|
6
Danaher
DHR
$147B
| $42M | 3.64% | 162,546 -17,113 | -10% | -$4.42M |
|
7
Sanofi
SNY
$121B
| $37.9M | 3.28% | 996,035 +116,575 | +13% | +$4.43M |
|
8
Teva Pharmaceuticals
TEVA
$21.1B
| $32.8M | 2.84% | 4,062,935 -447,767 | -10% | -$3.61M |
|
9
Syndax Pharmaceuticals
SNDX
$1.41B
| $29.1M | 2.52% | 1,211,434 +217,072 | +22% | +$5.22M |
|
10
Envista
NVST
$3.52B
| $20.8M | 1.8% | 633,001 -26,093 | -4% | -$856K |
|
|
11
Illumina
ILMN
$15.8B
| $20.4M | 1.77% | 107,002 +71,736 | +203% | +$13.7M |
|
12
Community Health Systems
CYH
$387M
| $19M | 1.65% | 8,841,604 +780,745 | +10% | +$1.68M |
|
13
Celldex Therapeutics
CLDX
$1.47B
| $17.6M | 1.53% | 626,372 +73,984 | +13% | +$2.08M |
|
14
Biogen
BIIB
$19.4B
| $16.1M | 1.39% | 60,144 -41,270 | -41% | -$11M |
|
15
Elevance Health
ELV
$71.8B
| $15M | 1.3% | 33,040 -9,745 | -23% | -$4.43M |
|
16
Centene
CNC
$14.3B
| $14.9M | 1.29% | 191,308 -42,339 | -18% | -$3.29M |
|
17
Lantheus
LNTH
$3.73B
| $14.6M | 1.26% | 206,893 +26,840 | +15% | +$1.89M |
|
|
AMRN
18
Amarin Corp
AMRN
$311M
| $13M | 1.13% | 11,962,744 -1,322,150 | -10% | -$1.44M |
|
|
ABMD
19
DELISTED
Abiomed Inc
ABMD
| $13M | 1.13% | 52,970 -16,327 | -24% | -$4.01M |
|
|
20
Seres Therapeutics
MCRB
$166M
| $12.4M | 1.08% | +1,935,825 | New | +$12.4M |
|
21
Humana
HUM
$36.5B
| $11.9M | 1.04% | 24,572 +13,402 | +120% | +$6.51M |
|
22
Viridian Therapeutics
VRDN
$1.5B
| $9.81M | 0.85% | 478,387 +32,795 | +7% | +$673K |
|
23
Amneal Pharmaceuticals
AMRX
$3B
| $9.48M | 0.82% | 4,690,812 -803,468 | -15% | -$1.62M |
|
24
Xenon Pharmaceuticals
XENE
$2.98B
| $9.37M | 0.81% | 259,612 -206,299 | -44% | -$7.45M |
|
25
Guardant Health
GH
$8.41B
| $9.23M | 0.8% | 171,481 -234,894 | -58% | -$12.6M |
|